Trial Profile
A Randomized, Placebo Controlled Clinical Trial to Evaluate the Effects of Simvastatin Treatment on Measurements of Lipidomic Biomarkers in Men With Dyslipidemia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Simvastatin (Primary)
- Indications Dyslipidaemias
- Focus Biomarker; Pharmacodynamics
- Acronyms COMPLETED
- Sponsors Merck & Co; Merck Sharp & Dohme Corp.
- 17 Feb 2012 Actual patient number changed from 40 to 31 as reported by ClinicalTrials.gov.
- 09 Sep 2010 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 31 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.